According to the CEO of Serum Institute of India, Adar Poonawalla the Oxford-AstraZeneca vaccine for the coronavirus disease might be available for the general public by April-May 2021 and is expected to cost near about ₹500-600 for one dose.
Expectations are that the efficient results will (from an ongoing UK trial of the vaccine) be reported in the coming three-four weeks. These results will pave the way for the companies to seek an emergency use licence – the government approval that will ultimately allow the first batch of shots to be given to people.
Initially the vaccines will be injected to the health workers and vulnerable people by as early as January or February.
The Oxford-AstraZeneca vaccine is proving to work very well, even in the old-aged people which was a huge concern early on due to lack of proper immunity actions in elderly. It elicits a good T-cell response and a good antibody response in the body.
In about 2-3 weeks, the efficacy results will be released.
This vaccine is India’s biggest hope against Covid-19 disease.
The vaccine in trials has largely turned out to be safe, can be stored and distributed with relative ease and, most crucially, is being manufactured by SII, an Indian company, which has promised to the people that it will reserve atleast half of the produced doses for the country.